Stocktoria
Medpace Holdings, Inc. MEDP
Nasdaq · stock · Services-Commercial Physical & Biological Research · website · IPO 2016-08-11 · LEI
Medpace Holdings, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.1B | $1.9B | $1.5B | $1.1B | $925.9M | $861.0M | $704.6M | $436.2M | $421.6M |
| SG&A expense | $197.6M | $180.2M | $161.4M | $131.4M | $108.4M | $92.2M | $95.2M | $75.7M | $63.4M | $61.5M |
| Operating income | $534.9M | $446.9M | $336.8M | $278.7M | $198.6M | $167.0M | $127.3M | $101.0M | $64.9M | $52.5M |
| Income tax | $91.3M | $71.5M | $52.9M | $37.5M | $20.0M | $23.1M | $24.4M | $20.8M | $17.8M | $8.5M |
| Net income | $451.1M | $404.4M | $282.8M | $245.4M | $181.8M | $145.4M | $100.4M | $73.2M | $39.1M | $13.4M |
| EPS (diluted) | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 | $3.84 | $2.67 | $1.97 | $0.98 | $0.37 |
| Operating cash flow | $713.2M | $608.8M | $433.4M | $388.1M | $263.3M | $258.7M | $201.9M | $156.6M | $97.4M | $91.7M |
| Free cash flow | $681.9M | $572.3M | $396.7M | $351.2M | $235.1M | $227.3M | $184.0M | $140.6M | $85.7M | $78.2M |
| Cash & equivalents | $497.0M | $669.4M | $245.4M | $28.3M | $461.3M | $277.8M | $131.9M | $23.3M | $26.5M | $37.1M |
| Total assets | $2.0B | $2.1B | $1.7B | $1.4B | $1.7B | $1.4B | $1.1B | $967.9M | $950.7M | $979.1M |
| Total liabilities | $1.5B | $1.3B | $1.1B | $966.1M | $707.0M | $584.9M | $416.8M | $378.2M | $447.2M | $368.4M |
| Shareholders' equity | $459.1M | $825.5M | $559.0M | $386.4M | $952.9M | $805.8M | $726.3M | $598.9M | $509.3M | $610.7M |
Growth · year-over-year · Revenue CAGR 22%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +20.0% | +11.8% | +29.2% | +27.8% | +23.4% | +7.5% | +22.2% | +61.5% | +3.5% | +17.4% |
| Net income growth | +11.6% | +43.0% | +15.3% | +34.9% | +25.1% | +44.7% | +37.2% | +87.1% | +191.4% | — |
| EPS growth | +21.0% | +42.2% | +22.0% | +51.4% | +25.3% | +43.8% | +35.5% | +101.0% | +164.9% | — |
| Free cash flow growth | +19.2% | +44.2% | +13.0% | +49.4% | +3.4% | +23.6% | +30.9% | +64.1% | +9.5% | -1.5% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.